BioSpace News Archive

Appili Therapeutics Inc. today announced that the U.S. Department of Defense (“DOD”), via the Joint Science and Technology Office of the Defense Threat Reduction Agency (“DTRA”), has selected for funding an Appili proposal that would provide over US$10 million to advance the Company’s biodefense vaccine candidate ATI-1701.

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a novel immuno-oncology panel discussion at the Cowen & Co. 42nd Annual Health Care Conference on Monday, March 7, 2022 at 10:30 a.m. ET.

CytomX Therapeutics, Inc. today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a virtual panel discussion at the Cowen 42nd Annual Healthcare Conference on Monday, March 7, 2022 at 12:50 p.m. ET.

CRISPR Therapeutics announced that members of its senior management team are scheduled to participate in the following investor conferences in March.

Impel NeuroPharma announced that Adrian Adams, Chairman and Chief Executive Officer, will participate in the following upcoming investor conferences.

PMV Pharmaceuticals, Inc. announced that David H. Mack, Ph.D., President & Chief Executive Officer, will participate in a panel discussion on lung cancer at the 42nd Annual Cowen Health Care Conference taking place virtually March 7-9, 2022.

Adverum Biotechnologies, Inc. announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Auditory and Ophthalmology panel discussion at the 42nd Annual Cowen Healthcare Conference on Monday, March 7, 2022, at 2:10 p.m. ET.

Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has issued patent No. 11,253,490 covering the use of its proprietary investigational abuse-deterrent formulation of dextroamphetamine, ADAIR, for the treatment of cognitive impairment (sometimes referred to as “COVID brain fog”) associated with COVID-19.

NGM Biopharmaceuticals, Inc. announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in the Cowen 42nd Annual Health Care Conference as part of the Novel Immuno-oncology Panel and will provide an overview of the company and a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Monday, March 7, at 10:30 am ET.

Global Blood Therapeutics, Inc. announced that it will participate in virtual fireside chats at the following investor conferences.